The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Inflammation and the Degenerative Diseases of Aging
Abstract
A bstract: Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases of aging. Included are such disorders as Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis, the Parkinson‐dementia complex of Guam, all of the tauopathies, and age‐related macular degeneration. Also included are such peripheral conditions as osteoarthritis, rheumatoid arthritis, atherosclerosis, and myocardial infarction. Inflammation is a two‐edged sword. In acute situations, or at low levels, it deals with the abnormality and promotes healing. When chronically sustained at high levels, it can seriously damage viable host tissue. We describe this latter phenomenon as autotoxicity to distinguish it from autoimmunity. The latter involves a lymphocyte‐directed attack against self proteins. Autotoxicity, on the other hand, is determined by the concentration and degree of activation of tissue‐based monocytic phagocytes. Microglial cells are the brain representatives of the monocyte phagocytic system. Biochemically, the intensity of their activation is related to a spectrum of inflammatory mediators generated by a variety of local cells. The known spectrum includes, but is not limited to, prostaglandins, pentraxins, complement components, anaphylotoxins, cytokines, chemokines, proteases, protease inhibitors, adhesion molecules, and free radicals. This spectrum offers a huge variety of targets for new anti‐inflammatory agents. It has been suggested, largely on the basis of transgenic mouse models, that stimulating inflammation rather than inhibiting it can be beneficial in such diseases as AD. If this were the case, administration of NSAIDs, or other anti‐inflammatory drugs, would be expected to exacerbate conditions such as AD, PD, and atherosclerosis. However, epidemiological evidence overwhelmingly demonstrates that the reverse is true. This indicates that, at least in these diseases, the inflammation is harmful. So far, advantage has not been taken of opportunities indicated by these epidemiological studies to treat AD and PD with appropriate anti‐inflammatory agents. Based on this evidence, classical NSAIDs are the most logical choice. Dosage, though, must be sufficient to combat the inflammation. Analysis of mRNA levels of inflammatory mediators indicates that the intensity of inflammation is considerably higher in AD hippocampus and in PD substantia nigra than in osteoarthritic joints. Thus, full therapeutic doses of NSAIDs, or combinations of anti‐inflammatory agents, are needed to achieve the suggested neurological benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
The many faces of macrophage activation
Mosser, D. M. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0602325 · Cited by 1,902
McGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Self-citationMCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287
Self-citationNonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993) · Glia · doi:10.1002/glia.440070117 · Cited by 1,029
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L. C., Hempelman, S. R., Berry, D. L., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 999
Self-citationComplement activation by beta-amyloid in Alzheimer disease.
Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., & Ward, P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.21.10016 · Cited by 817
Self-citationNonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Inflammation and neurodegeneration in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.01.005 · Cited by 625
Self-citationProduction of superoxide anions by a CNS macrophage, the microglia
Colton, C. A., & Gilbert, D. L. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80305-8 · Cited by 614
Alpha-2 macroglobulin is genetically associated with Alzheimer disease
Blacker, D., Wilcox, M. A., Laird, N. M., Rodes, L., Horvath, S. M., Go, R. C. P., Perry, R., Watson, B., Bassett, S. S., McInnis, M. G., et al. (1998) · Nature Genetics · doi:10.1038/1243 · Cited by 486
Inflammation, autotoxicity and Alzheimer disease
McGeer, P. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00289-5 · Cited by 478
Self-citationInflammatory processes in Alzheimer's disease
McGeer, E. G., & McGeer, P. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00124-6 · Cited by 472
Self-citationInflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
Self-citationA randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Expression of the histocompatibility glycoprotein HLA-DR in neurological disease
McGeer, P. L., Itagaki, S., & McGeer, E. G. (1988) · Acta Neuropathologica · doi:10.1007/bf00689592 · Cited by 420
Self-citationButterfield, D. A., & Kanski, J. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00249-4 · Cited by 419
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400
Self-citationNonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 397
A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease
Scharf, S., Mander, A., Ugoni, A., Vajda, F., & Christophidis, N. (1999) · Neurology · doi:10.1212/wnl.53.1.197 · Cited by 390
A randomized controlled trial of prednisone in Alzheimer’s disease
Koch, H. J., & Szecsey, A. (2000) · Neurology · doi:10.1212/wnl.55.7.1067 · Cited by 384
Chapman, G. A., Moores, K., Harrison, D., Campbell, C. A., Stewart, B. R., & Strijbos, P. J. L. M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-15-j0004.2000 · Cited by 349
(1950) · Physical Therapy · doi:10.1093/ptj/30.5.213b · Cited by 320
Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer’s disease
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02970-x · Cited by 300
Self-citationSpecific Domains of β-Amyloid from Alzheimer Plaque Elicit Neuron Killing in Human Microglia
Giulian, D., Haverkamp, L. J., Yu, J. H., Karshin, W., Tom, D., Li, J., Kirkpatrick, J., Kuo, Y.-M., & Roher, A. E. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-19-06021.1996 · Cited by 271
Webster, S., Lue, L.-F., Brachova, L., Tenner, A. J., McGeer, P. L., Terai, K., Walker, D. G., Bradt, B., Cooper, N. R., & Rogers, J. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00042-0 · Cited by 258
Self-citationYasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01389-x · Cited by 251
Self-citationCurrent View on the Mononuclear Phagocyte System
Van Furth, R. (1982) · Immunobiology · doi:10.1016/s0171-2985(82)80072-7 · Cited by 245
Van Gool, W. A., Weinstein, H. C., Scheltens, P. K., & Walstra, G. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05623-9 · Cited by 212
Histology and histopathology of the nervous system
Haymaker, W., & Adams, R. D. (1982) · Thomas eBooks · Cited by 195
Association of an interleukin 1α polymorphism with Alzheimer’s disease
Du, Y., Dodel, R. C., Eastwood, B. J., Bales, K. R., Gao, F., Lohmüller, F., Müller, U., Kurz, A., Zimmer, R., Evans, R. M., et al. (2000) · Neurology · doi:10.1212/wnl.55.4.480 · Cited by 195
Polymorphisms in Inflammatory Genes and the Risk of Alzheimer Disease
McGeer, P. L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.11.1790 · Cited by 192
Self-citationMcCusker, S. M., Curran, M. D., Dynan, K. B., McCullagh, C. D., Urquhart, D. D., Middleton, D., Patterson, C. C., McIlroy, S. P., & Peter Passmore, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04008-3 · Cited by 191
Papassotiropoulos, A., Bagli, M., Jessen, F., Bayer, T. A., Maier, W., Rao, M. L., & Heun, R. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199905)45:5<666::aid-ana18>3.0.co;2-3 · Cited by 186
Randomized pilot study of nimesulide treatment in Alzheimer’s disease
Aisen, P. S., Schmeidler, J., & Pasinetti, G. M. (2002) · Neurology · doi:10.1212/wnl.58.7.1050 · Cited by 176
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (1998) · Circulation Research · doi:10.1161/01.res.83.8.860 · Cited by 161
Self-citationAnti-inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Broe, G. A., Grayson, D. A., Creasey, H. M., Waite, L. M., Casey, B. J., Bennett, H. P., Brooks, W. S., & Halliday, G. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.11.1586 · Cited by 160
Microglia and the Process of Phagocytosis in Gliomas.
Penfield, W. G. (1925) · Europe PMC (PubMed Central) · Cited by 153
Leçons sur la pathologie comparée de l'inflammation
Metschnikoff, E. (1893) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0029-1205315 · Cited by 147
Immune system associated antigens expressed by cells of the human central nervous system
Luber‐Narod, J., & Rogers, J. (1988) · Neuroscience Letters · doi:10.1016/0304-3940(88)90263-7 · Cited by 146
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease
Schwab, C., Hosokawa, M., & McGeer, P. L. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.03.016 · Cited by 144
Self-citationNonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease
Ton, T. G. N., Heckbert, S. R., Longstreth, W. T., Jr., Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith‐Weller, T., & Checkoway, H. (2006) · Movement Disorders · doi:10.1002/mds.20856 · Cited by 141
The Nitration Product 5-Nitro-γ-tocopherol Is Increased in the Alzheimer Brain
Williamson, K. S., Gabbita, S. P., Mou, S., West, M. S., Pye, Q. N., Markesbery, W. R., Cooney, R. V., Grammas, P., Reimann‐Philipp, U., Floyd, R. A., et al. (2002) · Nitric Oxide · doi:10.1006/niox.2001.0399 · Cited by 139
Hippocampal damage mediated by corticosteroids — a neuropsychiatric research challenge
Höschl, C., & Hájek, T. (2001) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf03035134 · Cited by 135
Serum amyloid P component binds to histones and activates the classical complement pathway
Hicks, P. S., Saunero-Nava, L., Clos, T. W. D., & Mold, C. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.11.3689 · Cited by 130
Licastro, F., Pedrini, S., Ferri, C., Casadei, V. M., Govoni, M., Pession, A., Sciacca, F. L., Veglia, F., Annoni, G., Bonafè, M., et al. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3<388::aid-ana16>3.0.co;2-g · Cited by 130
Collins, J. S., Perry, R. T., Watson, B., Harrell, L. E., Acton, R. T., Blacker, D., Albert, M., Tanzi, R. E., Bassett, S. S., McInnis, M. G., et al. (2000) · American Journal of Medical Genetics · doi:10.1002/1096-8628(20001204)96:6<823::aid-ajmg26>3.0.co;2-i · Cited by 128
McGeer, P. L. (2000) · Drugs & Aging · doi:10.2165/00002512-200017010-00001 · Cited by 118
Self-citationAssociation of interleukin-1β polymorphisms with idiopathic Parkinson's disease
McGeer, P. L., Yasojima, K., & McGeer, E. G. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00300-2 · Cited by 118
Self-citationPolymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease
Schulte, T., Schöls, L. J., Müller, T. H., Woitalla, D., Berger, K., & Krüger, R. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00301-4 · Cited by 117
Jiang, H., Robey, F. A., & Gewurz, H. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.175.5.1373 · Cited by 107
Complement Components, but Not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq0701.092160 · Cited by 105
Self-citationHigh stability of mRNAs postmortem and protocols for their assessment by RT-PCR
Yasojima, K., McGeer, E. G., & McGeer, P. L. (2001) · Brain Research Protocols · doi:10.1016/s1385-299x(01)00119-2 · Cited by 97
Self-citationCompstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts
Fiane, A. E., Mollnes, T. E., Videm, V., Hovig, T., Högåsen, K., Mellbye, O. J., Spruce, L. A., Moore, W. T., Sahu, A., & Lambris, J. D. (1999) · Xenotransplantation · doi:10.1034/j.1399-3089.1999.00007.x · Cited by 93
Kalaria, R. N., & Grahovac, I. (1990) · Brain Research · doi:10.1016/0006-8993(90)90941-4 · Cited by 89
Rebeck, G. W. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01487-7 · Cited by 87
The pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases
McGeer, E. G., Yasojima, K., Schwab, C., & McGeer, P. L. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00288-3 · Cited by 83
Self-citationEtanercept in rheumatoid arthritis
Alldred, A. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.7.1137 · Cited by 83
Klegeris, A., Walker, D. G., & McGeer, P. L. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00014-3 · Cited by 75
Self-citationKlegeris, A., & McGeer, P. L. (1994) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)90067-1 · Cited by 74
Self-citationKlegeris, A., & McGeer, P. L. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.127 · Cited by 68
Self-citationThomas, M., Le, W. D., & Jankovic, J. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200301000-00005 · Cited by 62
Association of interleukin‐1 polymorphisms with Alzheimer's disease in Australia
Hedley, R., Hallmayer, J. F., Groth, D., Brooks, W. S., Gandy, S., & Martins, R. N. (2002) · Annals of Neurology · doi:10.1002/ana.10196 · Cited by 60
Yasojima, K., McGeer, E. G., & McGeer, P. L. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01514-0 · Cited by 58
Self-citationAssociation of amyloid P component with complement proteins in neurologically diseased brain tissue
Akiyama, H., Yamada, T., Kawamata, T., & McGeer, P. L. (1991) · Brain Research · doi:10.1016/0006-8993(91)91148-t · Cited by 58
Self-citationRegulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells
Klegeris, A., Walker, D. G., & McGeer, P. L. (1997) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(97)00094-5 · Cited by 56
Self-citationTumour necrosis factor-α blockade: a new era for effective management of rheumatoid arthritis
Hamilton, K., & Clair, E. W. S. T. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.1041 · Cited by 38
Nitric Oxide-Releasing Nsaids: a Novel Class of Gi-Sparing Anti-Inflammatory Drugs
Wallace, J. L., Pittman, Q. J., & Cirino, G. (1995) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7276-8_12 · Cited by 29
Wolfson, C. M., Perrault, A., Moride, Y., Esdaile, J. M., Abenhaim, L., & Momoli, F. (2002) · Neuroepidemiology · doi:10.1159/000048621 · Cited by 27
Disease modifying antirheumatic drugs: longterm safety issues.
Capell, H. A. (2001) · PubMed · Cited by 21
Kamboh, M. I., Aston, C. E., Ferrell, R. E., & DeKosky, S. T. (1997) · Genomics · doi:10.1006/geno.1996.4601 · Cited by 10
Aisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Langston, J. W., Forno, L. S., Tetrud, J., Reeves, A. G., Kaplan, J. A., & Karluk, D. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199910)46:4 · Cited by 1
Cann, S. A. H., Netten, J. P. V., & Netten, C. V. (2000) · Pure Amsterdam UMC · doi:10.1002/1531-8249(200003)47:3
Zujovic (2000) · doi:10.1002/(sici)1098-1136(20000215)29:4
Cited by
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
The role of inflammation in CNS injury and disease
Lucas, S., Rothwell, N. J., & Gibson, R. M. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706400 · Cited by 1,272
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974
Xu, M., Tchkonia, T., Ding, H., Ogrodnik, M., Lubbers, E. R., Pirtskhalava, T., White, T. A., Johnson, K. O., Stout, M. B., Mezera, V., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1515386112 · Cited by 915
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814
Metadata
- Authors
- McGEER, P. L., & McGEER, E. G.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2004-12
- Volume
- 1035
- Issue
- 1
- Pages
- 104-116
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2050206306
- Cited by
- 518
- References
- 78
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.